Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH-1: PLS240 for secondary hyperparathyroidism in hemodialysis
2023-504338-24-00Phase 3Completed
- Sponsor
- Pathalys Pharma
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) and end-stage kidney disease (ESKD) comparing PLS240 with Placebo (2 arms). Primary endpoints: Proportion of participants with ≥30% decrease in mean iPTH during EAP, Open-label safety assessments and 1 more. Started Sep 2023; status: completed.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2023-504338-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504338-24-00.